Get the Stockscreener App
1.39
2.11%
-0.03
After Hours:
1.39
Proqr Therapeutics N V stock is traded at $1.39, with a volume of 673.68K.
It is down -2.11% in the last 24 hours and down -17.26% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$1.42
Open:
$1.42
24h Volume:
673.68K
Relative Volume:
1.35
Market Cap:
$146.43M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-3.6695
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-4.79%
1M Performance:
-17.26%
6M Performance:
-27.23%
1Y Performance:
-37.95%
1-Day Range:
$1.33
$1.44
1-Week Range:
$1.33
$1.5528
52-Week Range:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.39 | 149.59M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Aug Levels: Is ProQR Therapeutics NV stock a buy or sellJuly 2025 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ProQR announces board changes as two members set to depart By Investing.com - Investing.com South Africa
ProQR announces board changes as two members set to depart - Investing.com
ProQR Therapeutics (PRQR) Announces Board Changes at Upcoming AG - GuruFocus
ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM - TipRanks
Co-founder among 2 ProQR directors set to leave board at 2026 AGM - Stock Titan
ProQR Therapeutics NV Announces Departure of Board Members Dinko Valerio and Alison Lawton - Longbridge
Myriad Genetics (NASDAQ:MYGN) & ProQR Therapeutics (NASDAQ:PRQR) Head-To-Head Survey - Defense World
ProQR Aktie: Pipeline-Fortschritte - Börse Global
Risk Recap: Will ProQR Therapeutics NV stock recover after earningsJuly 2025 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Dip Buying: Is Sharps Technology Inc Equity Warrant in a bullish channelWeekly Market Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Recap: Is ProQR Therapeutics NV a cyclical or defensive stockEarnings Trend Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Quarterly Earnings: Can ProQR Therapeutics NV weather a recessionWeekly Stock Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 28% - 富途牛牛
Aug PreEarnings: Is KFFB stock undervalued right nowTrade Entry Report & Weekly Stock Performance Updates - baoquankhu1.vn
Market Recap: Can SBEV be recession proofQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Earnings Miss: Can ProQR Therapeutics NV reach resistance levels soon2025 AllTime Highs & Expert Verified Movement Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Day Trade: Does OLMA have strong EBITDA marginsJuly 2025 Volume & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Published on: 2026-01-18 21:01:57 - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aug Patterns: What insider trading reveals about ProQR Therapeutics NV stockProfit Target & Consistent Growth Equity Picks - Bộ Nội Vụ
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st
Working capital per share of ProQR Therapeutics N.V. – FWB:0PQ - TradingView — Track All Markets
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com Nigeria
Will ProQR Therapeutics N.V. stock deliver long term returnsDip Buying & Free Community Consensus Stock Picks - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - Улправда
ProQR stock falls after initial AX-0810 data, pipeline updates - Investing.com
ProQR announces encouraging AX-0810 phase 1 - MarketScreener
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans - TipRanks
ProQR reports positive initial AX-0810 safety data in phase 1 trial By Investing.com - Investing.com South Africa
ProQR (PRQR) details encouraging AX-0810 Phase 1 data and 2026 plans - Stock Titan
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can ProQR Therapeutics N.V. (0PQ) stock sustain double digit ROEJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Can ProQR Therapeutics N.V. stock sustain market leadershipEarnings Date Calendar & Fast Profit Trading Strategies - Bollywood Helpline
How ProQR Therapeutics N.V. (0PQ) stock gains from tech spendingWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Can ProQR Therapeutics N.V. stock hit analyst price targetsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - Улправда
Is ProQR Therapeutics N.V. stock a safe haven assetJuly 2025 Catalysts & Weekly Breakout Watchlists - Улправда
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):